OpGen (NASDAQ:OPGN) posted its quarterly earnings data on Tuesday. The medical research company reported ($0.61) EPS for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.20, MarketWatch Earnings reports. The firm had revenue of $0.82 million during the quarter. OpGen had a negative return on equity of 662.90% and a negative net margin of 397.44%.
Shares of OPGN stock traded down $0.25 during trading on Wednesday, hitting $2.74. The company had a trading volume of 34,149 shares, compared to its average volume of 6,265,327. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.24 and a current ratio of 0.31. The firm has a market capitalization of $17.53 million, a P/E ratio of -0.11 and a beta of -1.01. The stock’s 50-day moving average price is $2.34 and its 200 day moving average price is $2.93. OpGen has a one year low of $0.92 and a one year high of $20.80.
Separately, Zacks Investment Research lowered OpGen from a “buy” rating to a “hold” rating in a research note on Wednesday, February 5th.
OpGen, Inc, a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.
See Also: S&P/TSX Index
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.